Patents by Inventor Leonid Reznikov

Leonid Reznikov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of apoptosis-specific eIF-5A(eIF-5A1?) with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics
    Patent number: 8754057
    Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: June 17, 2014
    Assignee: Senesco Technologies, Inc.
    Inventors: John E. Thompson, Bruce C. Galton, Catherine Taylor, Charles Dinarello, Leonid Reznikov, Adrienne Boone, Marianne Hopkins
  • Inhibition of Apoptosis-Specific eIF-5A(elF-5A1") with Antisense Oligonucleotides and siRNA as Anti-Inflammatory Therapeutics
    Publication number: 20120129910
    Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.
    Type: Application
    Filed: May 2, 2011
    Publication date: May 24, 2012
    Applicant: Senesco Technologies Inc.
    Inventors: John E. Thompson, Bruce C. Galton, Catherine Taylor, Charles Dinarello, Leonid Reznikov, Adrienne Boone, Marianne Hopkins
  • Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics
    Publication number: 20100168047
    Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFKB by inhibiting expression of apoptosis-specific eIF-5A.
    Type: Application
    Filed: May 23, 2005
    Publication date: July 1, 2010
    Inventors: John Thompson, Bruce Galton, Catherine Taylor, Charles Dinarello, Leonid Reznikov, Adrienne Boone, Marianne Hopkins
  • Nucleic acids, polypeptides, and methods for modulating apoptosis
    Patent number: 7217517
    Abstract: The present invention provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of reducing apoptosis in mammalian tissue, preferably heart tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5a is higher than proliferating eIF-5A. In the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A. Preferred agents are antisense oligonucleotides to human apoptosis-specific eIF-5A.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: May 15, 2007
    Assignee: Senesco Technologies, Inc.
    Inventors: John E. Thompson, Catherine Taylor, Dominic Cliche, Charles Dinarello, Leonid Reznikov, Benjamin Pomerantz
  • Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
    Publication number: 20070081975
    Abstract: The present invention provides a method of treatment or prevention of sepsis and other diseases characteristic to the Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock, and sepsis related to cardiac dysfunction.
    Type: Application
    Filed: August 16, 2006
    Publication date: April 12, 2007
    Inventors: Daniela Novick, Charles Dinarello, Menachem Rubinstein, Soo Kim, Giamila Fantuzzi, Leonid Reznikov, Boris Schwartsburd
  • Apoptosis-specific eIF-5A and polynucleotides encoding same
    Publication number: 20060287265
    Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for increasing or decreasing expression of apoptosis-specific eIF-5A. The invention also relates to methods of increasing or decreasing apoptosis.
    Type: Application
    Filed: December 5, 2005
    Publication date: December 21, 2006
    Inventors: John Thompson, Bruce Galton, Catherine Taylor, Charles Dinarello, Leonid Reznikov, Adrienne Boone, Marianne Hopkins
  • Use of apoptosis-specific eIF-5A siRNAs and antisense polynucleotides to inhibit/suppress an inflammatory response
    Publication number: 20060154887
    Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.
    Type: Application
    Filed: July 20, 2005
    Publication date: July 13, 2006
    Inventors: John Thompson, Bruce Galton, Catherine Taylor, Charles Dinarello, Leonid Reznikov, Adrienne Boone, Marianne Hopkins
  • Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics
    Publication number: 20060094677
    Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFKB by inhibiting expression of apoptosis-specific eIF-5A.
    Type: Application
    Filed: May 23, 2005
    Publication date: May 4, 2006
    Inventors: John Thompson, Bruce Galton, Catherine Taylor, Charles Dinarello, Leonid Reznikov, Adrienne Boone, Marianne Hopkins
  • Use of IL-18 inhibitors for the treatment and/or prevention of heart disease
    Publication number: 20040234523
    Abstract: The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of a heart disease, in particular ischemic heart disease. Combinations of an IL-18 inhibitor and/or a TNF antagonist are also considered for the treatment and/or prevention of a heart disease.
    Type: Application
    Filed: February 6, 2004
    Publication date: November 25, 2004
    Inventors: Charles Dinarello, Benjamin Pomerantz, Leonid Reznikov, Alden Harken, Yolande Chvatchko
  • Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs
    Publication number: 20040157930
    Abstract: The use of derivatives of hydroxamic acid having histone deacetylase enzyme-inhibiting activity for the preparation of anti-inflammatory medicaments is disclosed.
    Type: Application
    Filed: April 9, 2004
    Publication date: August 12, 2004
    Inventors: Paolo Mascagni, Flavio Leoni, Giulia Porro, Paolo Pagani, Giancarlo Dona, Pietro Pozzi, Charles Dinarello, Giamila Fantuzzi, Britta Siegmund, Leonid Reznikov, Philip Bufler, Soo Hyun Kim, Benjamin Pomeranz
  • Nucleic acids, polypeptides, and methods for modulating apoptosis
    Publication number: 20030144238
    Abstract: The present invention provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of reducing apoptosis in mammalian tissue, preferably heat tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5a is higher than proliferating eIF-5A. In the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A. Preferred agents are antisense oligonucleotides to human apoptosis-specific eIF-5A.
    Type: Application
    Filed: October 23, 2002
    Publication date: July 31, 2003
    Inventors: John E. Thompson, Catherine Taylor, Dominic Cliche, Charles Dinarello, Leonid Reznikov, Benjamin Pomerantz